Prescribers give thumbs up to Biotie/Lundbeck's Selincro
This article was originally published in Scrip
Selincro (nalmefene), the alcohol-dependence drug licensed to Lundbeck from Finnish firm Biotie, is going down well with prescribers, says Andreas Eggert, Lundbeck's senior vice-president of global product strategy & portfolio development. as the company prepares for its imminent launch in in the first markets where it has won reimbursement: the Netherlands and Denmark .
You may also be interested in...
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Brazil’s pharmaceutical industry has welcomed the election of medicines regulator ANVISA to the management committee of the International Council for Harmonization.